143945-72-6

Basic information

• Product Name: 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole
• Synonyms: N-(Triphenylmethyl)-5-(2-bromophenyl)-1H-tetrazole;5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole
• CAS NO: 143945-72-6
• Molecular Formula: C₂₆H₁₉BrN₄
• Molecular Weight: 467.36
• Product Categories: API intermediates
• Mol File: 143945-72-6.mol

Chemical Properties

• Boiling Point: 623.249 °C at 760 mmHg
• Flash Point: 330.729 °C
• Appearance: /
• Density: 1.33
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.668
• PKA: 0.16±0.10(Predicted)
• CAS DataBase Reference: 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole(143945-72-6)
• EPA Substance Registry System: 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole(143945-72-6)

Safety Data

• Hazardous Substances Data: 143945-72-6(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure and potential biological activities. Its incorporation into new molecules can lead to the development of drugs with novel therapeutic properties.
Used in Pharmaceutical Research:
In pharmaceutical research, 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole is utilized as a starting material for the design and synthesis of new drug candidates. Its tetrazole ring and attached functional groups can be modified to explore various chemical and biological properties, contributing to the discovery of innovative therapeutic agents.
Used in Organic Chemistry:
5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole is used as a subject of synthetic and computational studies in organic chemistry. Its structural complexity provides opportunities for exploring new synthetic pathways and understanding the relationship between its structure and reactivity, which can further enhance its applications in the development of pharmaceuticals and other chemical products.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole is employed as a versatile intermediate for the preparation of a variety of compounds. Its unique structure allows for the introduction of different functional groups, enabling the synthesis of diverse molecules with potential applications in various industries.
Used in Drug Discovery:
5-(2-Bromophenyl)-1-(triphenylmethyl)-1H-tetrazole is used as a potential lead compound in drug discovery. Its unique structural features and potential biological activities make it a promising candidate for further optimization and development into effective therapeutic agents targeting specific diseases or conditions.

InChI:InChI=1/C26H19BrN4/c27-24-19-11-10-18-23(24)25-28-29-30-31(25)26(20-12-4-1-5-13-20,21-14-6-2-7-15-21)22-16-8-3-9-17-22/h1-19H

Upstream product

• 73096-42-1 5-(2-bromophenyl)-1H-tetrazole 
• 76-83-5 trityl chloride 
• 123-91-1 1,4-dioxane 

Downstream Products

• 137862-53-4 N-pentanoyl-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]-methyl]-(L)-valine 
• 120568-18-5 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde 
• 124751-00-4 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 
• 138402-10-5 trityl irbesartan 
• 781664-81-1 N-[[2'-(1-triphenylmethyltetrazol-5yl)biphenyl-4-yl]methyl]-N-valeryl-L-valine methyl ester 
• 894793-42-1 tert-butyl N-pentanoyl-N-[{2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]-1,1'-biphenyl-4-yl}methyl]-L-valinate 
• 137864-44-9 N-[(2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl)methyl]-N-valeroyl-(L)-valine benzyl ester 
• 141887-45-8 ethyl 2-biphenyl-4-yl)-methyl>amino>pyridine-3-carboxylate 

Relevant articles and documents

METHOD FOR THE PRODUCTION OF LOSARTAN

The invention relates to a novel method for the production of losartan, an imidazol derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-]methyl}imidazol and the pharmacologically active salts thereof. The invention also relates to novel intermediate products which are suitable for the production of losartan, and to novel methods for the production of intermediate compounds which are suitable for the production of losartan. One aspect of the invention is a method for the production of a compound of general formula (I), which can arise as an intermediate step in the inventive representation of losartan.

5-aryleheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders

A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders such as hypertension. Compounds of particular interest are angiotensin II antagonists of the formula wherein A is selected from wherein m is one; wherein R1 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, benzyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, halo, difluoromethyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein each of R3, R4, R6 through R11 is hydrido and R5 is selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl.

N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS

A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula STR1 wherein A is selected from STR2 wherein m is one; wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 0 is hydrido; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R 3, R 4, R 6, R 7, R. sup.8, R 9, R 10 and R. sup.11 is hydrido and R 5 must be selected from COOH, SH, P0 3 H. sub.2, SO 3 H, CONHNH 2, CONHNHSO 2 CF 3, OH, STR3 wherein each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-aceptable salt thereof.

A novel and expeditious route to A-81988: An angiotensin II receptor antagonist

A novel and efficient synthesis of A-81988, an angiotensin II receptor antagonist, is described. The key step utilizes a palladium-catalyzed biaryl coupling between a phenylboronic acid derivative and N-trityl-5-(2-bromophenyl)tetrazole.

5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders

A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders such as hypertension. Compounds of particular interest are antiotensin II antagonists of the formula STR1 wherein A is selected from STR2 wherein m is one; wherein R1 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, benzyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, halo, difluoromethyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluor-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein each of R3, R4, R6 through R11 is hydrido and R5 is selected from COOH, SH, PO3 H2, SO3 H, CONHNH2, CONHNHSO2 CF3, OH, STR3 wherein each of R42 and R43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl.